GSK’s GSK’227 Secures the US FDA’s Breakthrough Therapy Designation for Treating Late-Line R/R Osteosarcoma
Shots:
- The US FDA has granted BTD to GSK5764227 (GSK’227) for treating r/r osteosarcoma in patients with disease progression on at least 2 prior lines of therapy
- Designation was supported by P-II (ARTEMIS-002) trial (carried out by Hansoh Pharma) assessing the safety & efficacy of GSK’227 to treat patients (n=60; 42 had osteosarcoma) with r/r osteosarcoma plus other unresectable bone & soft tissue sarcomas. Results were highlighted at ASCO 2024
- GSK’227 (HS-20093) is a B7-H3-targeted ADC developed by Hansoh Pharma for various solid tumors. In 2023, GSK acquired global rights (excl. China’s mainland, Hong Kong, Macau & Taiwan) for its development & launched a global P-I trial in Aug 2024
Ref: GSK | Image: GSK
Related News:- GSK’s GSK’227 Secures the EMA’s Priority Medicines (PRIME) Designation for Extensive-Stage Small-cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
